- Home
- WOOF vs GOSS Comparison
WOOF vs GOSS Comparison
Compare WOOF & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOOF | GOSS |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | 29000 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.9M | 726.8M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WOOF | GOSS |
|---|---|---|
| Price | $3.15 | $3.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $3.92 | ★ $8.60 |
| AVG Volume (30 Days) | ★ 3.5M | 2.9M |
| Earning Date | 11-25-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,998,469,000.00 | $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.76 | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.28 | $0.71 |
| 52 Week High | $5.09 | $3.60 |
Technical Indicators
Market Signals| Indicator | WOOF | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 65.88 |
| Support Level | $2.97 | $3.25 |
| Resistance Level | $3.24 | $3.54 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 54.12 | 92.62 |
Price Performance
Historical ComparisonAbout WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.